DNA Methyltransferase Inhibitor Zebularine Inhibits Human Hepatic Carcinoma Cells Proliferation and Induces Apoptosis

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Nakamura, Kazuaki ^a   Aizawa, Kazuko ^a   Nakabayashi, Kazuhiko ^a   Kato, Natsuko ^a   Yamauchi, Junji ^a   Hata, Kenichiro ^a   Tanoue, Akito ^a  

^a NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; DNA METHYLTRANSFERASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE R; PROTEIN P42; PROTEIN P44; RETINOBLASTOMA PROTEIN; ZEBULARINE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CELL STRAIN HEPG2; DNA METHYLATION; DOWN REGULATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASES; CELL PROLIFERATION; CYTIDINE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; PHOSPHORYLATION;

EID: 84872183961     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054036     Document Type: Article

References (59)

1. Altekruse SF, McGlynn KA, Reichman ME, (2009) Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27: 1485-1491.
2. El-Serag HB, Marrero JA, Rudolph L, Reddy KR, (2008) Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134: 1752-1763.
3. Thomas MB, Zhu AX, (2005) Hepatocellular carcinoma: the need for progress. J Clin Oncol 23: 2892-2899.
4. Llovet JM, Bruix J, (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48: 1312-1327.
5. Gan L, Chen S, Zhong J, Wang X, Lam EK, et al. (2011) ZIC1 is downregulated through promoter hypermethylation, and functions as a tumor suppressor gene in colorectal cancer. PLoS One 6: e16916.
6. Lin RK, Hsieh YS, Lin P, Hsu HS, Chen CY, et al. (2010) The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J Clin Invest 120: 521-532.
7. Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, et al. (2007) Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 117: 2713-2722.
8. Marques CJ, Joao Pinho M, Carvalho F, Bieche I, Barros A, et al. (2011) DNA methylation imprinting marks and DNA methyltransferase expression in human spermatogenic cell stages. Epigenetics 6: 1354-1361.
9. Kobayashi Y, Absher DM, Gulzar ZG, Young SR, McKenney JK, et al. (2011) DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res 21: 1017-1027.
10. Weisenberger DJ, Velicescu M, Cheng JC, Gonzales FA, Liang G, et al. (2004) Role of the DNA methyltransferase variant DNMT3b3 in DNA methylation. Mol Cancer Res 2: 62-72.
11. Qu Y, Mu G, Wu Y, Dai X, Zhou F, et al. (2010) Overexpression of DNA methyltransferases 1, 3a, and 3b significantly correlates with retinoblastoma tumorigenesis. Am J Clin Pathol 134: 826-834.
12. Amara K, Ziadi S, Hachana M, Soltani N, Korbi S, et al. (2010) DNA methyltransferase DNMT3b protein overexpression as a prognostic factor in patients with diffuse large B-cell lymphomas. Cancer Sci 101: 1722-1730.
13. Gravina GL, Festuccia C, Marampon F, Popov VM, Pestell RG, et al. (2010) Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer 9: 305.
14. Dote H, Cerna D, Burgan WE, Carter DJ, Cerra MA, et al. (2005) Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine. Clin Cancer Res 11: 4571-4579.
15. Issa JP, Kantarjian HM, (2009) Targeting DNA methylation. Clin Cancer Res 15: 3938-3946.
16. Neureiter D, Zopf S, Leu T, Dietze O, Hauser-Kronberger C, et al. (2007) Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models. Scand J Gastroenterol 42: 103-116.
17. Pinto A, Zagonel V, (1993) 5-Aza-2′-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia 7Suppl 1: 51-60.
18. Schwartsmann G, Schunemann H, Gorini CN, Filho AF, Garbino C, et al. (2000) A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest New Drugs 18: 83-91.
19. Andersen JB, Factor VM, Marquardt JU, Raggi C, Lee YH, et al. (2010) An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci Transl Med 2: 54-77.
20. Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, et al. (2004) Preferential response of cancer cells to zebularine. Cancer Cell 6: 151-158.
21. Hurd PJ, Whitmarsh AJ, Baldwin GS, Kelly SM, Waltho JP, et al. (1999) Mechanism-based inhibition of C5-cytosine DNA methyltransferases by 2-H pyrimidinone. J Mol Biol 286: 389-401.
22. Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, et al. (2003) Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 95: 399-409.
23. Yoo CB, Cheng JC, Jones PA, (2004) Zebularine: a new drug for epigenetic therapy. Biochem Soc Trans 32: 910-912.
24. Cheng JC, Weisenberger DJ, Gonzales FA, Liang G, Xu GL, et al. (2004) Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 24: 1270-1278.
25. Feinberg AP, (2004) The epigenetics of cancer etiology. Semin Cancer Biol 14: 427-432.
26. Feinberg AP, Ohlsson R, Henikoff S, (2006) The epigenetic progenitor origin of human cancer. Nat Rev Genet 7: 21-33.
27. Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, et al. (2011) High density DNA methylation array with single CpG site resolution. Genomics 98: 288-295.
28. Wang D, Yan L, Hu Q, Sucheston LE, Higgins MJ, et al. (2012) IMA: an R package for high-throughput analysis of Illumina's 450K Infinium methylation data. Bioinformatics 28: 729-730.
29. Billam M, Sobolewski MD, Davidson NE, (2010) Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res Treat 120: 581-592.
30. You BR, Park WH, (2012) Zebularine inhibits the growth of HeLa cervical cancer cells via cell cycle arrest and caspase-dependent apoptosis. Mol Biol Rep 39: 9723-9731.
31. Taya Y, (1997) RB kinases and RB-binding proteins: new points of view. Trends Biochem Sci 22: 14-17.
32. Dai XY, Zeng XX, Peng F, Han YY, Lin HJ, et al. (2012) A novel anticancer agent, SKLB70359, inhibits human hepatic carcinoma cells proliferation via G0/G1 cell cycle arrest and apoptosis induction. Cell Physiol Biochem 29: 281-290.
33. Yang X, Chan C, (2009) Repression of PKR mediates palmitate-induced apoptosis in HepG2 cells through regulation of Bcl-2. Cell Res 19: 469-486.
34. Ben-Kasus T, Ben-Zvi Z, Marquez VE, Kelley JA, Agbaria R, (2005) Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells. Biochem Pharmacol 70: 121-133.
35. Fandy TE, (2009) Development of DNA methyltransferase inhibitors for the treatment of neoplastic diseases. Curr Med Chem 16: 2075-2085.
36. Harbour JW, Dean DC, (2000) Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol 2: E65-67.
37. Obaya AJ, Sedivy JM, (2002) Regulation of cyclin-Cdk activity in mammalian cells. Cell Mol Life Sci 59: 126-142.
38. Di Leonardo A, Linke SP, Clarkin K, Wahl GM, (1994) DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 8: 2540-2551.
39. Gartel AL, Tyner AL, (1999) Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res 246: 280-289.
40. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, et al. (1994) Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54: 3391-3395.
41. Russo T, Zambrano N, Esposito F, Ammendola R, Cimino F, et al. (1995) A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J Biol Chem 270: 29386-29391.
42. Serfas MS, Goufman E, Feuerman MH, Gartel AL, Tyner AL, (1997) p53-independent induction of p21WAF1/CIP1 expression in pericentral hepatocytes following carbon tetrachloride intoxication. Cell Growth Differ 8: 951-961.
43. Shen G, Xu C, Chen C, Hebbar V, Kong AN, (2006) p53-independent G1 cell cycle arrest of human colon carcinoma cells HT-29 by sulforaphane is associated with induction of p21CIP1 and inhibition of expression of cyclin D1. Cancer Chemother Pharmacol 57: 317-327.
44. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
45. Waldman T, Kinzler KW, Vogelstein B, (1995) p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55: 5187-5190.
46. Hubina E, Nanzer AM, Hanson MR, Ciccarelli E, Losa M, et al. (2006) Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur J Endocrinol 155: 371-379.
47. Motomura W, Tanno S, Takahashi N, Nagamine M, Fukuda M, et al. (2005) Involvement of MEK-ERK signaling pathway in the inhibition of cell growth by troglitazone in human pancreatic cancer cells. Biochem Biophys Res Commun 332: 89-94.
48. Tu Y, Wu W, Wu T, Cao Z, Wilkins R, et al. (2007) Antiproliferative autoantigen CDA1 transcriptionally up-regulates p21(Waf1/Cip1) by activating p53 and MEK/ERK1/2 MAPK pathways. J Biol Chem 282: 11722-11731.
49. Tsukada Y, Tanaka T, Miyazawa K, Kitamura N, (2004) Involvement of down-regulation of Cdk2 activity in hepatocyte growth factor-induced cell cycle arrest at G1 in the human hepatocellular carcinoma cell line HepG2. J Biochem 136: 701-709.
50. Leist M, Gantner F, Bohlinger I, Germann PG, Tiegs G, et al. (1994) Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-alpha requires transcriptional arrest. J Immunol 153: 1778-1788.
51. Liedtke C, Plumpe J, Kubicka S, Bradham CA, Manns MP, et al. (2002) Jun kinase modulates tumor necrosis factor-dependent apoptosis in liver cells. Hepatology 36: 315-325.
52. Orrenius S, McConkey DJ, Bellomo G, Nicotera P, (1989) Role of Ca2+ in toxic cell killing. Trends Pharmacol Sci 10: 281-285.
53. Samali A, Nordgren H, Zhivotovsky B, Peterson E, Orrenius S, (1999) A comparative study of apoptosis and necrosis in HepG2 cells: oxidant-induced caspase inactivation leads to necrosis. Biochem Biophys Res Commun 255: 6-11.
54. Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, et al. (1998) Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 42: 442-447.
55. Nicholson DW, Thornberry NA, (1997) Caspases: killer proteases. Trends Biochem Sci 22: 299-306.
56. Samonakis DN, Moschandreas J, Arnaoutis T, Skordilis P, Leontidis C, et al. (2002) Treatment of hepatocellular carcinoma with long acting somatostatin analogues. Oncol Rep 9: 903-907.
57. Tsagarakis NJ, Drygiannakis I, Batistakis AG, Kolios G, Kouroumalis EA, (2011) Octreotide induces caspase activation and apoptosis in human hepatoma HepG2 cells. World J Gastroenterol 17: 313-321.
58. Proud CG, (1995) PKR: a new name and new roles. Trends Biochem Sci 20: 241-246.
59. Taylor SS, Haste NM, Ghosh G, (2005) PKR and eIF2alpha: integration of kinase dimerization, activation, and substrate docking. Cell 122: 823-825.